CELF1 (CUGBP Elav-like family member 1), also known as CUG-BP1. is an RNA-binding protein belonging to the CELF family, which regulates post-transcriptional gene expression. It plays critical roles in RNA splicing, editing, stability, and translation by binding to GU-rich elements in target mRNAs. CELF1 is involved in diverse biological processes, including muscle development, neuronal function, and cell cycle regulation. Dysregulation of CELF1 has been implicated in several diseases. Notably, it is linked to myotonic dystrophy type 1 (DM1), where its aberrant splicing activity contributes to pathological RNA toxicity caused by CUG repeat expansions. In cancer, CELF1 overexpression is associated with tumor progression, metastasis, and poor prognosis in malignancies such as breast, lung, and colorectal cancers, often by modulating oncogenic or tumor-suppressive mRNAs. Additionally, CELF1 interacts with neurodegeneration-related proteins like TDP-43. suggesting potential roles in amyotrophic lateral sclerosis (ALS) and Alzheimer’s disease.
CELF1 antibodies are essential tools for studying its expression, localization, and molecular interactions. They are widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to investigate CELF1's tissue-specific distribution, disease-related dysregulation, and mechanistic pathways. Some antibodies target specific isoforms or post-translational modifications, aiding in functional studies. Research using CELF1 antibodies has highlighted its dual roles in health and disease, making it a potential therapeutic target. However, variability in CELF1 expression across tissues and disease stages underscores the need for antibody validation in specific experimental contexts. These studies continue to advance understanding of RNA-binding proteins in cellular homeostasis and pathogenesis.